Lazard Asset Management’s Xeris Biopharma Holdings XERS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-11,182
| Closed | -$61K | – | 2558 |
|
|
2025
Q1 | $61K | Sell |
11,182
-205,511
| -95% | -$1.12M | ﹤0.01% | 1952 |
|
|
2024
Q4 | $734K | Sell |
216,693
-161,646
| -43% | -$548K | ﹤0.01% | 1255 |
|
|
2024
Q3 | $1.08M | Sell |
378,339
-257,905
| -41% | -$735K | ﹤0.01% | 1053 |
|
|
2024
Q2 | $1.43M | Buy |
636,244
+215,757
| +51% | +$485K | ﹤0.01% | 900 |
|
|
2024
Q1 | $929K | Buy |
420,487
+16,674
| +4% | +$36.8K | ﹤0.01% | 936 |
|
|
2023
Q4 | $948K | Buy |
403,813
+88,326
| +28% | +$207K | ﹤0.01% | 965 |
|
|
2023
Q3 | $586K | Buy |
315,487
+190,049
| +152% | +$353K | ﹤0.01% | 1109 |
|
|
2023
Q2 | $328K | Sell |
125,438
-164,012
| -57% | -$429K | ﹤0.01% | 1219 |
|
|
2023
Q1 | $471K | Sell |
289,450
-56,932
| -16% | -$92.6K | ﹤0.01% | 1118 |
|
|
2022
Q4 | $460K | Sell |
346,382
-61,227
| -15% | -$81.3K | ﹤0.01% | 1141 |
|
|
2022
Q3 | $635K | Sell |
407,609
-116,685
| -22% | -$182K | ﹤0.01% | 1059 |
|
|
2022
Q2 | $807K | Sell |
524,294
-1,828,305
| -78% | -$2.81M | ﹤0.01% | 1025 |
|
|
2022
Q1 | $6.02M | Sell |
2,352,599
-128,076
| -5% | -$328K | 0.01% | 729 |
|
|
2021
Q4 | $7.27M | Buy |
2,480,675
+2,330,568
| +1,553% | +$6.83M | 0.01% | 711 |
|
|
2021
Q3 | $367K | Buy |
150,107
+137,558
| +1,096% | +$336K | ﹤0.01% | 1215 |
|
|
2021
Q2 | $51K | Sell |
12,549
-67,948
| -84% | -$276K | ﹤0.01% | 1596 |
|
|
2021
Q1 | $363K | Sell |
80,497
-16,097
| -17% | -$72.6K | ﹤0.01% | 1026 |
|
|
2020
Q4 | $475K | Buy |
96,594
+68,194
| +240% | +$335K | ﹤0.01% | 984 |
|
|
2020
Q3 | $168K | Buy |
+28,400
| New | +$168K | ﹤0.01% | 978 |
|